SCHEMBL20262189

SCHEMBL20262189

CCCCCC/C=C\COC(=O)CBr

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 6/20 0.59
TERT O14746 3/20 0.49
PTPN1 P18031 3/20 0.49
PPARG P37231 3/20 0.49
PPARD Q03181 3/20 0.49
PPARA Q07869 3/20 0.49
TOP1 P11387 3/20 0.49
CYP1A2 P05177 2/20 0.49
MAPT P10636 2/20 0.49
CYP2C19 P33261 2/20 0.49
BLM P54132 2/20 0.49
HSD17B10 Q99714 2/20 0.49
FABP4 P15090 2/20 0.49
KMT2A Q03164 2/20 0.49
GMNN O75496 1/20 0.49
USP2 O75604 1/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
CYP2C9 P11712 1/20 0.49
ALOX15 P16050 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20262190 1.00 FAAH (0.59) FAAHTERTPTPN1PPARGPPARD
SCHEMBL20262144 0.87 DGKA (0.55) FAAHCYP1A2MAPTCYP2C19BLM
SCHEMBL20262145 0.87 DGKA (0.55) FAAHCYP1A2MAPTCYP2C19BLM
SCHEMBL514368 0.86 FAAH (0.77) FAAHMAPTNPSR1
SCHEMBL514366 0.86 FAAH (0.77) FAAHMAPTNPSR1
SCHEMBL22981998 0.86 DGKA (0.56) FAAHTERTPTPN1PPARGPPARD
SCHEMBL8961932 0.86 NAAA (0.55) FAAHTERTPTPN1PPARGPPARD
SCHEMBL8961986 0.86 NAAA (0.55) FAAHTERTPTPN1PPARGPPARD
SCHEMBL25228444 0.86 DGKA (0.56) FAAHTERTPTPN1PPARGPPARD
SCHEMBL8495250 0.86 DGKA (0.56) FAAHTERTPTPN1PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637422-B2 Ionizable cationic lipid for RNA delivery ARCTURUS THERAPEUTICS, INC. (US) 2026-05-26 US disclosed
US-20260131020-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS INC (US) 2026-05-14 US disclosed
US-12527881-B2 Ionizable cationic lipid for RNA delivery ARCTURUS THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
EP-4527831-A2 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY Arcturus Therapeutics, Inc. (US) 2025-03-26 EP disclosed
EP-4310075-A2 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY Arcturus Therapeutics, Inc. (US) 2024-01-24 EP disclosed
EP-4310075-A2 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY Arcturus Therapeutics, Inc. (US) 2024-01-24 EP disclosed
EP-3558943-B1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS INC (US) 2023-10-18 EP disclosed
EP-3558943-B1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS INC (US) 2023-10-18 EP disclosed
EP-3558942-B1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS INC (US) 2023-09-06 EP disclosed
EP-3558942-B1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS INC (US) 2023-09-06 EP disclosed
WO-2018119163-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY PAYNE JOSEPH E (US) 2018-06-28 WO disclosed
WO-2018119163-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY PAYNE JOSEPH E (US) 2018-06-28 WO disclosed
WO-2018118102-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. (US) 2018-06-28 WO disclosed
WO-2018118102-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. (US) 2018-06-28 WO disclosed
US-20180170866-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2018-06-21 US disclosed
US-20180170866-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2018-06-21 US disclosed
US-20180169268-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2018-06-21 US disclosed
US-20180169268-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2018-06-21 US disclosed
US-20180170866-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2018-06-21 US disclosed
US-20180169268-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2018-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260131020-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY SLC27A1, NSUN3, SLC10A1 FAAH 1291/4885TERT 1675/4885PTPN1 3322/4885
US-20180170866-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY RNASEH1, RNASE1, HNRNPA1 FAAH 1465/4885TERT 1965/4885PTPN1 4602/4885
US-20180169268-A1 IONIZABLE CATIONIC LIPID FOR RNA DELIVERY RNASEH1, RNASE1, HNRNPA1 FAAH 1854/4885TERT 1682/4885PTPN1 4524/4885
US-12637422-B2 Ionizable cationic lipid for RNA delivery POLRMT, SLC27A1, SLC43A1 FAAH 890/4885TERT 1175/4885PTPN1 2544/4885
US-12527881-B2 Ionizable cationic lipid for RNA delivery NSUN3, SLC27A1, SLC43A1 FAAH 1373/4885TERT 2035/4885PTPN1 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.